cethromycin

Trade name: Restanza

Small moleculeexperimental

Cethromycin, trade name Restanza is a ketolide antibiotic undergoing research for the treatment of community acquired pneumonia (CAP) and for the prevention of post-exposure inhalational anthrax, and was given an "orphan drug" status for this indication. Originally discovered and developed by Abbott, it was acquired by Advanced Life Sciences Inc. for further development. — Wikipedia

Clinical trial activity

2 trials · 1 clinical orgs · 0 marketing orgs

Phase 1

Phase 2

Phase 3

Phase 4

Earliest trial started Dec 1, 2005 (NCT00336505)

Timeline

2000s

Jan 1, 2005
Earliest Phase 3 Sponsor(trial)

Indications

Studied for

Pneumonia · Phase 3

Mechanism of action

Chemistry & pharmacology

Loading structure…

SMILES

CC[C@H]1OC(=O)[C@H](C)C(=O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(OCC=Cc2cnc3ccccc3c2)C[C@@H](C)C(=O)[C@H](C)[C@H]2NC(=O)O[C@@]21C

Mol. weight: 765.95 g/mol
Lipinski Ro5: 3 violation(s)
Rule of 3: No
Chirality: Single Stereoisomer
Inorganic: No
Polymer: No

Oral

Parenteral

Topical

Sources

Also known as

a 195773
a 195,773
a-195773
a-195773
a-195773
a-195,773
abbott-195773
abbott-195773
abt 773
abt-773
abt-773
abt-773
cethromycin
cethromycin
cethromycin
cethromycin
cethromycin

Clinical trials

NCT ID	Phase	Start date	Sponsor(s)
NCT00336544	Phase 3	Jun 1, 2006	Advanced Life Sciences
NCT00336505	Phase 3	Dec 1, 2005	Advanced Life Sciences

Showing 2 of 2 trials

Page 1 / 1

Organizations

Research & Development (1)

Organization	Org type	Trials	As lead sponsor	Phases	Earliest year
Advanced Life Sciences	For profit	2	2	1	2005

1 organizations

Page 1 / 1